ArticleFrontiers in nutrition2026
Multidimensional repair of jujube pectic oligosaccharides on bone marrow hematopoietic failure.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jujube, a valued resource in traditional practices for both medicine and diet, has been historically recognized for its blood-nourishing properties. Nevertheless, the potential of its active constituent, Jujube Pectic Oligosaccharides (JOL), to ameliorate myelosuppressive anemia remains poorly understood. This research was therefore designed to elucidate the therapeutic efficacy and underlying mechanism of JOL using a murine model of cyclophosphamide-induced myelosuppression. Our findings demonstrate that JOL administration effectively restored multi-lineage peripheral blood cell counts, improved the structural integrity of the spleen and bone marrow, and modulated key hematopoietic factors. These critical factors comprised erythropoietin (EPO), Flt3 ligand (Flt3-L), thrombopoietin (TPO), and granulocyte colony-stimulating factor (G-CSF). Collectively, the results indicate that Jujube oligosaccharides could mitigate myelosuppressive anemia via synergistic multi-target effects, possibly by rehabilitating the damaged hematopoietic microenvironment and normalizing the cytokine network equilibrium. This investigation offers foundational experimental support for the development of JOL as a promising therapeutic candidate for myelosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.